Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05815095

Early Detection and Referral for Autism and Neurodevelopmental Disorders at the Maternal and Child Protection Services

This study aims to compare two screening strategies for identifying infants with a potential risk of Autism Spectrum and Neurodevelopmental Disorders to provide early access to care and increase the likelihood of a favorable outcome

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 month–12 month

Sex eligibility

All sexes

Study type

Observational

Primary location

PMI Stalingrad

Champigny-sur-Marne, 94500, France

Location status: Recruiting

Location contact

Catherine DELMAS, MD

CONTACT

0147064925

About this study

This prospective cohort study is performed at several Maternal and Child Protection Services in France. It aims to early detect infants under 12 months of age with a developmental gap compared to that expected for their age.

The first consultation will occur at the same time as the infant's usual medical follow-up at the Maternal and Child Protection Service (usually vaccination in the fourth month and developmental examination at nine months). Two strategies will be evaluated during this visit to assess the infant's neurodevelopmental characteristics. In the first one, a health professional will assess the infant's neurodevelopmental characteristics through routine practice evaluations, such as motor skills, vocalizations, babbling, and social interactions. In the second one, the PREAUT grid will be used for screening of screening for autism spectrum disorder.

Patients with abnormal results in these evaluations would be referred to a specialized center early for advice and treatment if necessary. We will consider an early referral as the referral of infants to an adapted consultation within the month following the first consultation. Also, these patients will be assessed using the State-Trait Anxiety Inventory-Form Y and T and the QUALIN score.

After 12 months of follow-up, data regarding the received treatments of patients who were addressed to a specialized center will be performed.

At 24 and 36 months of follow-up, all the included patients will be assessed with the Modified Checklist for Autism in Toddlers, Revised with Follow-up instrument (M-CHAT-R/F) ,and the IDE ( the French version of the Child Development Inventory). In case of an abnormal result of the M-CHAT-R/F, the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) will be administered. In case of an abnormal result of the IDE, the Brunet-Lézine scale will be administered.

Finally, the French health insurance claims databases will be used to evaluate the care pathway of all included patients up to 48 months of the child.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

in

  • Infants between 4 and 9 months of age followed up in the participating Maternal and Child Protection Services for the fourth and ninth-month mandatory vaccinations
  • Availability of a personnel telephone for at least one parent
  • Information to the parents for data collection and the active follow-up of the child until 36 months and express consent to participate in the research
  • Affiliation to a social security system or benefiting from the Medical assistance of the state
  • Mastery of a minimum of French according to the principal investigator or the presence of a French-speaking relative

Exclusion criteria

  • Infant with a severe neurological pathology such as encephalopathy
  • Refusal to participate in the study

Treatment and study plan

PREAUT grid

Other

Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary

Primary outcomes

  1. Proportion of children at 24 months with an Autism Spectrum Disorder or Neurodevelopmental Disorder diagnosis who received care before the age of one

    Time frame: At 2 years of age

Secondary outcomes

  1. Effectiveness of two screening strategies on the occurrence severity of Autism Spectrum Disorders (ASD) and Neurodevelopmental Disorders (NDD)

    Time frame: At 2 and 3 years of age

  2. Predictive performance of the PREAUT grid (at four months and nine months) compared to the usual diagnosis

    Time frame: At 2 and 3 years of age

  3. Association between ASD-NDD diagnosis and neonatal or familial risk factors

    Time frame: At 2 and 3 years of age of child's referral to the Medical psychological center

  4. Quality of life assessed by the QUALIN score

    Time frame: At inclusion in Maternal and Child Protection Services or at Medical-psychological center and at 2 and 3 years of age

  5. Measurement of the parents' psychological state at the time of the child's referral to the Medical psychological center

    Time frame: At a Medical-psychological center and at 2 and 3 years of age

  6. Impact on the family life (IOFS) of a child diagnosed with risk of Autism Spectrum and Neurodevelopmental Disorders

    Time frame: At 2 and 3 years of age

  7. Evaluation of the implementation of the new model of systematic screening of infants in Maternal and Child Protection Services and systematic referral to the Medical-psychological center

    Time frame: Through study completion, an average of 4 years

  8. Evaluation of the implementation of infant care in the Medical-psychological center

    Time frame: Through study completion, an average of 4 years

  9. Qualitative study of the incentives and obstacles of the screening and early referral strategy with the Maternal and Child Protection Service's workers

    Time frame: Through study completion, an average of 4 years

  10. Qualitative study of the screening and early referral strategy with parents

    Time frame: Through study completion, an average of 4 years

  11. Description of the practice of identification by the Maternal and Child Protection Services and referral to the Medical-psychological center

    Time frame: At the inclusion, at the end of inclusion and at the late visit

  12. Description of the care pathway in the two groups

    Time frame: At 4 years of the child

Study contacts

Contact information is provided by the study sponsor or research team.

Camille JUNG, MD

CONTACT

[email protected]

01 57 02 22 68

Catherine DELMAS, MD

CONTACT

[email protected]

01 47 06 49 25

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Intercommunal Creteil

Other

Registry information

Official study title

Randomized Pragmatic, Cluster, Stepped-wedge Trial of Early Detection and Referral for Autism and Neurodevelopmental Disorders at the Maternal and Child Protection Services for Care Before 1 Year of Follow-up

Important dates

Study start
2025
Primary completion
2030
Study completion
2032
First posted
Apr 18, 2023
Registry last updated
Jun 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.